HESI ITC Cancer Immunotherapies: Biology, Therapeutic Approaches and Immune Related Safety Assessments

Wed, April 22 2020, 9:00 AM - Thu, April 23 2020, 5:00 PM [RST]

2, Calle de Severo Ochoa, Tres Cantos, Comunidad de Madrid, 28760, Spain

Register Now

1. Select Seats

2. Review and Proceed

REGISTRATION

Sale ended

Private Sector Attendee PARTIAL APPROVAL - $800.00

sales ended

Public Sector Attendee PARTIAL APPROVAL - $500.00

Sale ended

Speaker PARTIAL APPROVAL

sales ended

HESI ITC TRAVEL GRANT recipients PARTIAL APPROVAL

Sale ended

Early Bird-Public Sector PARTIAL APPROVAL - $300.00

sales ended

Early Bird- Industry PARTIAL APPROVAL - $600.00

Enter your discount code

  • Subtotal (excluding fees and discounts)
  • Fee
  • Total amount

Wed, April 22 2020, 9:00 AM - Thu, April 23 2020, 5:00 PM [RST]

Glaxo Smith Kline Consumer Healthcare, 2, Tres Cantos, Comunidad de Madrid, 28760, Spain.

The field of immunotoxicology is a dynamic one in which changing public health concerns, novel biomedical research advances, and innovative technological developments constantly change the landscape and the way in which work is carried out and utilized. As this field requires combined expertise in both immunology and toxicology, the need for continued training and interdisciplinary interactions are critical for those who work within this field. This is essential both for those with an immunology background who seek to apply this expertise to drug development and safety, as well as those who wish to enhance their current drug safety expertise with a deeper understanding of immunology.

Objectives:

-Review the background science of the immune system in both normal and diseased state

-Enhance awareness of toxicities associated with the modulation of the immune system

-Provide a training mechanism that incorporates the latest science into preexisting drug development methodologies

Output:

Beyond the dialogue that will be generated on the latest science, this training course will provide the opportunity to apply late-breaking science in a drug development setting through the following means:

-Engagement and discussion with experts in the field will enable participants to see how the science translates to applicability in drug development

-The use of specific case studies will engage and illustrate to participants how they can systematically progress on a sample task

To view the draft agenda, please visit the HESI event page: https://hesiglobal.org/event/cancer-immunotherapies-biology-therapeutic-approaches-and-immune-related-safety-assessments-2/

Event Registration

Health and Environmental Sciences Institute (HESI) was established in 1989 to provide an international forum to advance the understanding of scientific issues related to human health, toxicology, risk assessment, and the environment. In 2002, the U.S. Internal Revenue Service granted HESI tax-exempt status as a publicly supported, independently charted, charitable scientific organization pursuant to Section 501(c)(3) of the Internal Revenue Code. HESI’s scientific programs bring together scientists from around the world from academia, industry, governmental institutions, and research institutes and foundations to address and reach consensus on human and environmental health issues that have the potential to be resolved through creative applications of intellectual and financial resources The mission of the HESI Immuno-safety Technical Committee (ITC) is to identify and address scientific issues related to immune safety and translation to human health risk assessment. Key Objectives: Leverage technical and scientific expertise from academic, regulatory, and industry organizations to advance immuno-safety science Contribute to the scientific decision-making processes relative to the development of guidelines and regulations for immune safety testing Educate stakeholders in safety science and promote the understanding and appropriate use of immune safety data

CONTACT ORGANIZER